HK.02256 — —
  • 和誉医药与礼来达成19亿美元战略合作，共同推进创新药研发

    和誉医药宣布与全球制药巨头礼来签署战略研究合作及授权协议，潜在总金额高达19亿美元，涉及多个疾病靶点的创新药研发。协议涵盖首付款、里程碑付款及阶梯式销售分成，是近年来中国生物医药企业与跨国药企合作的又一里程碑事件。

📊 在监控面板里跟踪 HK.02256 —— 添加到 watchlist，配合价格 + 舆情双触发的告警规则，命中即时通过 Telegram / 邮件推送。

🗂️ All Tools

RedianPro one-stop tool index — 22 dedicated function pages. Data auto-refreshes every 30 min to 1 hour.

📋BriefingTonight's pre-market read📰Daily WrapWhat happened today🌡️Sectors11 SPDR sector ETFs📅Earnings14d earnings + FOMC📝InsidersSEC Form 4 ≥ $1M🏛️Fed MacroFOMC + Fed speeches📈Yield Curve11 tenors + inversion📊CFTC COTHedge fund positioning₿Crypto12 coins + Fear/Greed⛽CommoditiesGold / Oil / Ag🐉China ADRsADR ⇆ HK arb🔥WSB HeatRetail social Top 50🏆LeaderboardMost-watched tickers🚀52w HighMomentum signals📉52w LowReversal candidates🔎ScreenerMulti-dim filter⚖️Compare30 metrics side-by-side🧮CalculatorsDCF / IV / Sharpe🤖AI Q&ANatural language query🔍SearchSite-wide search📚Glossary100+ EN-CN terms📈PortfolioClient-side simulator📑NewsDaily Chinese digest